# EDGAR Filing Document

**Accession Number:** 0001907108
**File Stem:** 0000950170-25-082440
**Filing Date:** 2025-6
**Character Count:** 3636
**Document Hash:** 2cfdebe9acf974b7a422e96fe72adb86
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-25-082440.hdr.sgml**: 20250605

**ACCESSION NUMBER**: 0000950170-25-082440

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250605

**DATE AS OF CHANGE**: 20250605

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Lexeo Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001907108
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 854012572
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41855
- **FILM NUMBER:** 251027834

**BUSINESS ADDRESS:**
- **STREET 1:** 345 PARK AVENUE SOUTH
- **STREET 2:** FLOOR 6
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10010
- **BUSINESS PHONE:** (212) 547-9879

**MAIL ADDRESS:**
- **STREET 1:** 345 PARK AVENUE SOUTH
- **STREET 2:** FLOOR 6
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10010

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 14A INFORMATION**

**Proxy Statement Pursuant to Section 14(a) of the** 

**Securities Exchange Act of 1934** 

**(Amendment No.)** 

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

☐ Preliminary Proxy Statement

☐ **Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**

☐ Definitive Proxy Statement

☒ Definitive Additional Materials

☐ Soliciting Material Pursuant to §240.14a-11(c) or §240.14a-2

**LEXEO THERAPEUTICS, INC.**

**(Name of Registrant as Specified In Its Charter)**

------

**(Name of Person(s) Filing Proxy Statement, if other than the Registrant)**

Payment of Filing Fee (Check the appropriate box):

☒ No fee required.

☐ Fee paid previously with preliminary materials.

☐ Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.

------

Dear Stockholder:

This proxy statement supplement, dated June 5, 2025 (this "Supplement"), supplements the definitive proxy statement on Schedule 14A of Lexeo Therapeutics, Inc. a Delaware corporation (the "Company"), filed with the Securities and Exchange Commission on April 28, 2025 (the "Proxy Statement"), for the 2025 Annual Meeting of Stockholders (the "Annual Meeting") of the Company to be held on Thursday, June 26, 2025.

**Amendment and Restatement of Non-Employee Director Compensation Policy** 

The Company maintains a non-employee director compensation policy (the "Policy"). On June 2, 2025, the Company's compensation committee (the "Compensation Committee") of the board of directors (the "Board") approved changes to the non-employee director compensation program to increase the size of equity awards granted to Eligible Directors (as defined in the Proxy Statement) pursuant to the Policy.

The amended Policy provides that each Eligible Director upon first becoming a director receives an initial option to purchase 50,000 shares of common stock (the "Initial Grant"). Additionally, each Eligible Director automatically receives an annual option to purchase 25,000 shares (the "Annual Grant"), effective on the date of each annual meeting of the stockholders. All other terms of our Policy as described in the Proxy Statement, including the vesting of the Initial Grant and Annual Grant, remain in effect.

**THIS SUPPLEMENT SHOULD BE READ IN CONJUNCTION WITH THE PROXY STATEMENT. EXCEPT AS SPECIFICALLY SUPPLEMENTED BY THE INFORMATION CONTAINED HEREIN, THIS SUPPLEMENT DOES NOT MODIFY ANY OTHER INFORMATION SET FORTH IN THE PROXY STATEMENT.** 

------